Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant that compounding pharmacies prepare as oral capsules and oral liquids in individualized strengths.
Fluoxetine is an SSRI. It blocks the transporter that pulls serotonin back into nerve endings, which increases serotonin signaling in the brain; it has little effect on norepinephrine reuptake. The reference label is Prozac capsules (Dista Products Company, a Lilly subsidiary), which FDA lists as discontinued; fluoxetine is manufactured as generic capsules, tablets, an oral solution, a once-weekly delayed-release capsule and a fixed combination with olanzapine. Prozac is FDA-approved for major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder, with pediatric approval for depression and OCD, and, together with olanzapine, for bipolar I depression and treatment-resistant depression. Prescribers may order fluoxetine compounded when a patient needs a strength between manufactured ones, a very small dose for a slow taper, a capsule free of a specific dye or allergen, or a liquid in a different concentration or flavor. Compounded preparations are not FDA-approved and require a prescription.
Fluoxetine carries the FDA boxed warning for antidepressants: it increased the risk of suicidal thoughts and behavior in children, adolescents and young adults in short-term studies, so anyone starting or changing a dose should be watched for worsening mood, agitation or thoughts of self-harm. Do not take it with an MAOI, linezolid, intravenous methylene blue, pimozide or thioridazine; two weeks must pass after stopping an MAOI, and five weeks after stopping fluoxetine before starting an MAOI or thioridazine. Other label warnings cover serotonin syndrome (including with St. John's wort or tryptophan), QT prolongation, bleeding with aspirin, NSAIDs or warfarin, low sodium, mania, seizures, angle-closure glaucoma and withdrawal symptoms if stopped abruptly. Fluoxetine strongly inhibits CYP2D6, raising levels of many other drugs. Late-pregnancy use may cause persistent pulmonary hypertension or adaptation problems in the newborn, and fluoxetine reaches breast milk at higher levels than most SSRIs. If side effects are severe or persist, talk to your prescriber or pharmacist.
Fluoxetine inhibits the presynaptic serotonin transporter with mild 5-HT2A and 5-HT2C activity and minimal norepinephrine reuptake effect. Oral bioavailability is reported as 70 to 90 percent (StatPearls; the label gives no percentage) and food does not affect it; protein binding is about 94.5 percent; CYP2D6 converts it to the active metabolite norfluoxetine, which inhibits CYP3A4, and about 7 percent of patients are CYP2D6 poor metabolizers. Elimination half-lives are long, 1 to 3 days for fluoxetine after a single dose and 4 to 6 days at steady state, and 4 to 16 days for norfluoxetine, so dose changes take weeks to be reflected in plasma and the MAOI washout after stopping is five weeks. Labeled indications (Prozac): MDD, OCD, bulimia nervosa, panic disorder, pediatric MDD and OCD, and, with olanzapine, bipolar I depression and treatment-resistant depression. Prescribers have ordered fluoxetine off-label for premenstrual dysphoric disorder, binge eating disorder, social anxiety disorder, PTSD, Raynaud phenomenon and selective mutism (StatPearls, 2024); compounded liquids and low-strength capsules let them individualize those regimens and tapers. Dosing per prescriber, with attention to CYP2D6 status and interacting drugs. Monitoring: suicidality at initiation and dose changes, mania, serotonin syndrome, sodium where hyponatremia risk exists, bleeding risk, and ECG where QT risk factors exist; some anesthesia guidance suggests holding fluoxetine about five weeks before interventional spine procedures.
Swallow each capsule whole with a glass of water, unless your label says otherwise. Do not crush, chew or open the capsule unless your pharmacist tells you it is safe to do so. Take it at the times shown on your prescription label. If you miss a dose or are unsure how to take it, call the pharmacy.
Capsules are nonaqueous, so under USP <795> they usually carry a beyond-use date of up to 180 days when no other stability data apply. Keep the vial tightly closed at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard any capsules left after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
